- Lisdexamfetamine
- L-Lysine-d-amphetamine
- N-[(2S)-1-Phenylpropan-2-yl]-L-lysinamide
- (2S)-2,6-Diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide
Calderon, SN; Klein, M. A regulatory perspective on the abuse potential evaluation of novel stimulant drugs in the United States Neuropharmacology, 1 Dec 2014, 87, 97-103. 266 kB. https://doi.org/10.1016/j.neuropharm.2014.04.001
Chambers, SA; DeSousa, JM; Huseman, ED; Townsend, SD. The DARK side of total synthesis: Strategies and tactics in psychoactive drug production ACS Chem. Neurosci., 17 Oct 2018, 9 (10), 2307–2330. 8.1 MB. https://doi.org/10.1021/acschemneuro.7b00528 #124
Wenthur, CJ. Classics in Chemical Neuroscience: Methylphenidate ACS Chem. Neurosci., 17 Aug 2016, 7 (8), 1030–1040. 531 kB. https://doi.org/10.1021/acschemneuro.6b00199 #14
Bork, W; Dahlenburg, R; Gimbel, M; Jacobsen-Bauer, A; Zörntlein, S. Herleitung Von Grenzwerten Der „nicht Geringen Menge“ Im Sinne Des Btmg Toxichem Krimtech, 1 Jan 2019, 86 (1), 5–91. 4.4 MB. #AP-011
Elliott, SP; Holdbrook, T; Brandt, SD. Prodrugs of new psychoactive substances (NPS): A new challenge J. Forensic Sci., 13 Jan 2020, 65 (3), 913-920. 815 kB. https://doi.org/10.1111/1556-4029.14268 #Lisdexamfetamine MS,UV
Kamb, V. Analytical profile of lisdexamfetamine dimesylate (Vyvanse™) JCLIC, 1 Mar 2008, 18 (2), 3-6. 365 kB. MS,IR